References
- McAllisterHAJrHallRJCooleyDATumors of the heart and pericardiumCurr Probl Cardiol19992425711610028128
- JamaGMScarciMBowdenJMarciniakSJPalliative treatment for symptomatic malignant pericardial effusionInteract Cardiovasc Thorac Surg20141961019102625142067
- KlattECHeitzDRCardiac metastasesCancer1990656145614592306690
- SkhvatsabajaLVSecondary malignant lesions of the heart and pericardium in neoplastic diseaseOncology19864321031063951784
- MartinoniACipollaCMCivelliMIntrapericardial treatment of neoplastic pericardial effusionHerz200025878779311200128
- OidaTMimatsuKKanoHPericardiocentesis with cisplatin for malignant pericardial effusion and tamponadeWorld J Gastroenterol201016674074420135723
- ChenLKXuGCLiangYYangQYZhangLNIntrapericardial infusion of etoposide and cisplatin in treating malignant pericardial effusion of non-small cell lung cancerAi Zheng2006254505508 Chinese16613690
- MillaireAWurtzABrullardBValue of pericardioscopy in patients with pericardial effusion. A propos of 20 patientsArch Mal Coeur Vaiss198881910711076 French3143329
- ZhouWBBaiMJinYDiagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusionsInt J Tuberc Lung Dis200913338138619275801
- NagyJADvorakAMDvorakHFVascular hyperpermeability, angiogenesis, and stroma generationCold Spring Harb Perspect Med201222a00654422355795
- SriramKBRelanVClarkeBEDiagnostic molecular biomarkers for malignant pleural effusionsFuture Oncol20117673775221675837
- MidgleyRKerrDBevacizumab – current status and future directionsAnn Oncol2005167999100415939715
- RibeiroSCVargasFSAntonangeloLMonoclonal anti-vascular endothelial growth factor antibody reduces fluid volume in an experimental model of inflammatory pleural effusionRespirology20091481188119319818055
- LuoJCYamaguchiSShinkaiAShitaraKShibuyaMSignificant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumorsCancer Res19985812265226609635593
- El-ShamiKElsaidAEl-KermYOpen-label safety and efficacy pilot trial of intraperitoneal bevacizumab as palliative treatment in refractory malignant ascitesJ Clin Oncol20072518 Suppl9043
- NumnumTMRocconiRPWhitworthJBarnesMNThe use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinomaGynecol Oncol2006102342542816797681
- DuNLiXLiFIntrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusionOncol Rep20132962332234023525453